gemcitabine + recombinant human endostatin + carrellizumab

This is a combination regimen consisting of three agents: - **Gemcitabine** is a nucleoside analog used as a chemotherapeutic agent. It inhibits DNA synthesis by incorporating into DNA during replication, leading to cell death, particularly in rapidly dividing tumor cells. - **Recombinant human endostatin** (commonly known as Endostar) is an antiangiogenic protein that inhibits vascular endothelial growth factor (VEGF)-mediated angiogenesis, thereby reducing blood supply to tumors and inhibiting their growth and metastasis[3][2]. - **Carrellizumab** (likely intended to be camrelizumab; no evidence for "carrellizumab" exists in the literature or regulatory databases) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor. It enhances antitumor immunity by blocking the PD-1/PD-L1 pathway. The combination aims to synergistically inhibit tumor growth through direct cytotoxicity (gemcitabine), antiangiogenesis (recombinant human endostatin), and immune checkpoint blockade (carrellizumab/camrelizumab). This regimen has been investigated primarily for advanced non-small cell lung cancer and other solid tumors.